Full-Time

Head Global Talent Acquisition Delivery Leader

Posted on 5/9/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
People & HR (1)
Required Skills
Six Sigma
Workday HRIS
Human Resources Information System (HRIS)
Requirements
  • Experience: 14+ years of progressive HR or Talent Acquisition operations experience, including 5+ years in Talent Acquisition delivery leadership within large, matrixed, or global organizations
  • Education: Bachelor’s or master’s degree or relevant experience
  • Technical & Domain Expertise: Proven experience managing external workforce programs, Talent Acquisition operations, or global mobility administration
  • Technical & Domain Expertise: Proficiency with Workday Recruiting, SAP Fieldglass, or equivalent Vendor Management System and HR systems
  • Technical & Domain Expertise: Deep understanding of HR compliance frameworks, vendor governance, and risk management
  • Technical & Domain Expertise: Strong data literacy with ability to interpret and act on operational metrics and experience insights
  • Core Competencies: Strategic leadership and program execution in complex, global environments
  • Core Competencies: Ability to influence across HR, Legal, Procurement, and senior business leaders
  • Core Competencies: Operational rigor with strong focus on compliance and governance
  • Core Competencies: Analytical mindset and passion for process improvement and experience optimization
  • Core Competencies: Excellent communication, stakeholder management, and vendor relationship skills
  • Desirable: PMP, Lean Six Sigma, or equivalent operational excellence qualification
Responsibilities
  • Lead the global Talent Acquisition Delivery Tower, driving strategic and operational excellence across all facets of Talent Acquisition operations
  • Partner with the Talent Acquisition COE to operationalize hiring strategies, workforce plans, and process standards that support Amgen’s growth and innovation goals
  • Establish a scalable delivery framework that ensures agility, compliance, and a superior candidate and manager experience
  • Drive alignment between regional delivery teams, business stakeholders, and enabling functions (HR Technology, Data, Transformation, Innovation, Procurement, and Legal)
  • Oversee the global External Workforce Management program, ensuring effective use of contingent, consultant, and outsourced talent
  • Partner with Procurement, Legal, and HR to govern supplier relationships, optimize vendor performance, and ensure alignment with regulatory and SOX compliance requirements
  • Manage the relationship with Master Service Providers (MSPs) and Vendor Management System (VMS) tools (e.g., SAP Fieldglass) for full lifecycle management -sourcing through offboarding
  • Implement governance mechanisms and dashboards to monitor external workforce utilization, spend, and compliance
  • Provide insights to leadership to support strategic workforce planning and total talent management
  • Lead the Global Mobility Administration function, overseeing relocation, immigration, and assignment management activities in partnership with Global Mobility COE and external vendors
  • Ensure governance and compliance with local and international labour laws, tax requirements, and mobility policies
  • Standardize and optimize global mobility administrative processes to enhance employee experience and operational consistency
  • Partner with external relocation providers to manage cost efficiency, service quality, and global governance
  • Drive operational excellence across recruitment administration, requisition management, offer processing, and onboarding support functions
  • Ensure efficient coordination between recruiters, HR operations, and hiring managers to deliver a seamless and compliant hiring experience
  • Lead continuous improvement initiatives within TA administration to streamline workflows, reduce cycle times, and enhance candidate and hiring manager experience
  • Oversee adherence to global data integrity and compliance standards within Workday Recruiting and associated HR systems
  • Define and monitor key performance indicators (KPIs) across all towers -including service delivery metrics, experience measures, and compliance outcomes
  • Lead regular performance reviews with internal stakeholders and vendor partners to ensure accountability and service excellence
  • Serve as a trusted partner to HR and business leaders, providing data-driven insights, process recommendations, and operational updates
  • Champion cross-functional alignment between TA, HR, Legal, Procurement, and Global Mobility to ensure cohesive service delivery
  • Key Deliverables: Integrated Talent Acquisition Delivery Framework spanning external workforce, mobility, and TA operations
  • Key Deliverables: Global governance model for compliance, audit readiness, and vendor performance
  • Key Deliverables: Measurable improvements in hiring process efficiency, candidate satisfaction, and service quality
  • Key Deliverables: Actionable data and insights driving workforce and mobility planning decisions
  • Key Deliverables: Strong partnership ecosystem across HR, business functions, and external vendors
Desired Qualifications
  • PMP, Lean Six Sigma, or equivalent operational excellence qualification

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
  • Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
  • Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.

What critics are saying

  • Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
  • FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
  • Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.

What makes Amgen unique

  • Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
  • MariTide advances in Phase III obesity trials with monthly dosing.
  • UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Amgen who can refer or advise you

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.